Back to Search Start Over

Molecular classification of outcomes from dengue virus -3 infections.

Authors :
Brasier AR
Zhao Y
Wiktorowicz JE
Spratt HM
Nascimento EJ
Cordeiro MT
Soman KV
Ju H
Recinos A 3rd
Stafford S
Wu Z
Marques ET Jr
Vasilakis N
Source :
Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology [J Clin Virol] 2015 Mar; Vol. 64, pp. 97-106. Date of Electronic Publication: 2015 Jan 17.
Publication Year :
2015

Abstract

Objectives: Dengue virus (DENV) infection is a significant risk to over a third of the human population that causes a wide spectrum of illness, ranging from sub-clinical disease to intermediate syndrome of vascular complications called dengue fever complicated (DFC) and severe, dengue hemorrhagic fever (DHF). Methods for discriminating outcomes will impact clinical trials and understanding disease pathophysiology.<br />Study Design: We integrated a proteomics discovery pipeline with a heuristics approach to develop a molecular classifier to identify an intermediate phenotype of DENV-3 infectious outcome.<br />Results: 121 differentially expressed proteins were identified in plasma from DHF vs dengue fever (DF), and informative candidates were selected using nonparametric statistics. These were combined with markers that measure complement activation, acute phase response, cellular leak, granulocyte differentiation and viral load. From this, we applied quantitative proteomics to select a 15 member panel of proteins that accurately predicted DF, DHF, and DFC using a random forest classifier. The classifier primarily relied on acute phase (A2M), complement (CFD), platelet counts and cellular leak (TPM4) to produce an 86% accuracy of prediction with an area under the receiver operating curve of >0.9 for DHF and DFC vs DF.<br />Conclusions: Integrating discovery and heuristic approaches to sample distinct pathophysiological processes is a powerful approach in infectious disease. Early detection of intermediate outcomes of DENV-3 will speed clinical trials evaluating vaccines or drug interventions.<br /> (Copyright © 2015 Elsevier B.V. All rights reserved.)

Details

Language :
English
ISSN :
1873-5967
Volume :
64
Database :
MEDLINE
Journal :
Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology
Publication Type :
Academic Journal
Accession number :
25728087
Full Text :
https://doi.org/10.1016/j.jcv.2015.01.011